Yuange He Selected Research

Bevacizumab (Avastin)

1/2024

An epidermal growth factor receptor-mutated lung adenocarcinoma patient with brain lesions resisted to osimertinib monotherapy but achieved more than 4 years of survival in osimertinib plus bevacizumab metronomic treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuange He Research Topics

Disease

3	Adenocarcinoma of Lung 01/2024 - 01/2022
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 08/2022
3	Neoplasms (Cancer) 01/2024 - 01/2022
1	Breast Neoplasms (Breast Cancer) 08/2022
1	Lung Neoplasms (Lung Cancer) 08/2022
1	Brain Neoplasms (Brain Tumor) 01/2022
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2021
1	Parotid Neoplasms 01/2021

Drug/Important Bio-Agent (IBA)

3	ErbB Receptors (EGF Receptor)IBA 01/2024 - 01/2022
3	Tyrosine Kinase InhibitorsIBA 01/2024 - 01/2022
2	CrizotinibIBA 01/2022 - 01/2021
1	osimertinibIBA 01/2024
1	Bevacizumab (Avastin)FDA Link 01/2024
1	Immune Checkpoint InhibitorsIBA 08/2022
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 08/2022
1	sintilimabIBA 08/2022
1	niraparibIBA 08/2022
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 08/2022
1	Pemetrexed (MTA)FDA Link 01/2022
1	TropomyosinIBA 01/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 08/2022 - 01/2022
2	Therapeutics 08/2022 - 01/2022
1	Immunotherapy 08/2022
1	Molecular Targeted Therapy 08/2022